Key result
Intrinsic ATP was highly cost-effective compared to conventional ATP for managing ventricular tachyarrhythmias, yielding an ICER of $13,114 per QALY.
Why the study?
Conventional antitachycardia pacing reduces ICD shocks with variable effectiveness, prompting evaluation of the cost-effectiveness of a novel intrinsic ATP algorithm designed to optimize ventricular tachycardia termination.
Does Intrinsic ATP (iATP) improve cost-effectiveness compared to conventional ATP for terminating ventricular tachyarrhythmias in ICD patients?
Does Intrinsic ATP (iATP) improve cost-effectiveness compared to conventional ATP for terminating ventricular tachyarrhythmias in ICD patients?
Effect estimate: ICER $13,114 per QALY
Absolute Event Rate: 10.51% vs 10.33%
Intrinsic ATP is a highly cost-effective strategy compared to conventional ATP for managing ventricular tachyarrhythmias in ICD patients in the US, with an ICER well below the standard willingness-to-pay threshold.
ABSTRACT Background Ventricular tachyarrhythmias are potentially life-threatening arrhythmias commonly managed with implantable cardioverter-defibrillators (ICDs). Conventional antitachycardia pacing (ATP) can reduce ICD shocks, but its effectiveness varies. Intrinsic ATP (iATP) is a novel algorithm designed to optimize VT termination and minimize shocks. Objective To evaluate the cost-effectiveness of iATP versus conventional ATP for terminating ventricular tachyarrhythmias in the United States (US). Methods A Markov simulation model was developed to compare lifetime costs, survival, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER) of iATP versus conventional ATP in ICD patients. Model inputs were derived from published literature, and analyses were performed from the perspective of an integrated US healthcare system. Sensitivity analyses assessed the robustness of findings. Results Compared to conventional ATP, iATP was associated with additional QALYs (10.51 vs. 10.33) and additional lifetime costs ($4,014 vs. $1,673), resulting in a discounted ICER of $13,114 per QALY. The ICER is below the US willingness-to-pay (WTP) threshold ($120,000/QALY). The finding of cost effectiveness persisted across all sensitivity analyses. Conclusion iATP was associated with clinical benefits and was determined to be a highly cost-effective strategy for managing ventricular tachyarrhythmias in ICD patients. The ICER remains below the WTP threshold in both deterministic and probabilistic sensitivity analyses, demonstrating the robustness of the findings.
No takes yet. Share an insight, caveat, or question.
Zweibel et al. (2026) studied Ventricular tachyarrhythmias. Intrinsic ATP (iATP) vs. Conventional antitachycardia pacing (ATP) was evaluated on Incremental cost-effectiveness ratio (ICER) (ICER $13,114 per QALY). Intrinsic ATP was highly cost-effective compared to conventional ATP for managing ventricular tachyarrhythmias, yielding an ICER of $13,114 per QALY.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: